Beschreibung

Risk of bias assessment for randomized controlled trials of curcumin in ulcerative colitis evaluates domains including randomization, blinding, and outcome reporting across included studies.

Figure 2

Chart

Source Paper

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Nutrients (2020)

PMID: 32751776

DOI: 10.3390/nu12082296

Cite This Figure

![Figure 2: Risk of bias assessment for randomized controlled trials of curcumin in ulcerative colitis evaluates domains including randomization, blinding, and outcome reporting across included studies.]()

> Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." *Nutrients*, 2020. PMID: [32751776](https://pubmed.ncbi.nlm.nih.gov/32751776/)

<figure>
  <img src="" alt="Risk of bias assessment for randomized controlled trials of curcumin in ulcerative colitis evaluates domains including randomization, blinding, and outcome reporting across included studies." />
  <figcaption>Figure 2. Risk of bias assessment for randomized controlled trials of curcumin in ulcerative colitis evaluates domains including randomization, blinding, and outcome reporting across included studies.<br>  Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751776/">32751776</a></figcaption>
</figure>

Beschreibung

Figure 2

Source Paper

Cite This Figure

Verwandte Evidenz